ARCUTIS BIOTHERAPEUTICS INC's ticker is ARQT and the CUSIP is 03969K108. A total of 79 filers reported holding ARCUTIS BIOTHERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $161,222 | -36.7% | 30,362 | +13.7% | 0.00% | – |
| Q2 2023 | $254,518 | -36.2% | 26,707 | -26.4% | 0.00% | – |
| Q1 2023 | $399,223 | +7.2% | 36,293 | +44.2% | 0.00% | – |
| Q4 2022 | $372,546 | +7.1% | 25,172 | +38.3% | 0.00% | – |
| Q3 2022 | $348,000 | -7.4% | 18,204 | +3.1% | 0.00% | – |
| Q2 2022 | $376,000 | +28.3% | 17,649 | +16.2% | 0.00% | – |
| Q1 2022 | $293,000 | -16.8% | 15,191 | -10.5% | 0.00% | – |
| Q4 2021 | $352,000 | -8.3% | 16,969 | +5.5% | 0.00% | – |
| Q3 2021 | $384,000 | -22.0% | 16,087 | -10.8% | 0.00% | – |
| Q2 2021 | $492,000 | +2.5% | 18,033 | +8.6% | 0.00% | – |
| Q1 2021 | $480,000 | -85.3% | 16,605 | -85.7% | 0.00% | -100.0% |
| Q4 2020 | $3,261,000 | +1032.3% | 115,935 | +1081.2% | 0.00% | – |
| Q3 2020 | $288,000 | +101.4% | 9,815 | +107.7% | 0.00% | – |
| Q2 2020 | $143,000 | +31.2% | 4,725 | +29.2% | 0.00% | – |
| Q1 2020 | $109,000 | – | 3,658 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Frazier Life Sciences Management, L.P. | 8,684,232 | $46,113,272 | 3.06% |
| Pivotal bioVenture Partners Investment Advisor LLC | 1,105,309 | $5,869,191 | 2.34% |
| Bain Capital Life Sciences Investors, LLC | 3,000,000 | $15,930,000 | 1.78% |
| Sio Capital Management, LLC | 635,969 | $3,376,995 | 1.04% |
| Rubric Capital Management LP | 5,034,530 | $26,733,354 | 1.00% |
| Tejara Capital Ltd | 309,179 | $1,641,740 | 0.93% |
| AlphaCentric Advisors LLC | 165,000 | $876,150 | 0.50% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,135,227 | $6,028,055 | 0.33% |
| Orbimed Advisors | 1,914,479 | $10,165,883 | 0.22% |
| Two Seas Capital LP | 164,807 | $875,125 | 0.18% |